

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY DOCKET NO. TSRI 419.0 Con 1		SERIAL NO. 09/081,522	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Brooks, et al			
				FILING DATE 5/19/98		GROUP <del>1648</del> 1644	
U.S. PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
<i>Ne</i>		5,092,885	3/3/92	YAMADA ET AL. <small>U.S. Patent</small>			
<i>W</i>		5,112,946	5/12/92	MALONE <small>U.S. Patent</small>			
<i>W</i>		5,192,744	3/9/93	BOUCK ET AL. <small>U.S. Patent</small>			
<i>W</i>		5,202,352	4/13/93	OKADA ET AL. <small>U.S. Patent</small>			

FOREIGN PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<i>W</i>		8905155	6/15/89	PCT			
<i>W</i>		0 576 898 A2	6/15/93	European Patent			
<i>M</i>		0 578 083 A2	6/26/93	European Patent			
<i>M</i>		8906356	7/27/89	PCT			
<i>M</i>		9320229	10/14/93	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)


<i>W</i>	1	Davis, et al., "Identification of a Role of the Vitronectin Receptor and Protein Kinase C in the Induction of Endothelial Cell Vascular Formation", <u>J. of Cell. Biochem.</u> 51: 206-218 (1993)
	2	Folkman, et al., "Angiogenic Factors", <u>Science</u> 235: 442-447 (1987)
	3	Moses, et al., "Identification of an Inhibitor of Neovascularization from Cartilage", <u>Science</u> 248: 1408-1410 (1990)
	4	Folkman, et al., "Inhibition of Angiogenesis", <u>Cancer Bio.</u> 3: 89-96 (1992)
	5	Blood, et al., "Tumor Interactions with the Vasculature: Angiogenesis and Tumor Metastasis", <u>Biochim. et Biophys. Acta</u> 1032: 89-118 (1990)
	6	Ingber, et al., "Inhibition of Angiogenesis through Modulation of Collagen Metabolism", <u>Lab. Invest.</u> 59 (1): 44-51 (1988)
	7	Aumailley, et al., "Arg-Gly-Asp Constrained within Cyclic Pentapeptides: Strong and Selective Inhibitors of Cell Adhesion to Vitronectin and Laminin - Fragment P1", <u>Fed. of Euro. Biochem. Soc.</u> 291 (1): 50-54 (1991)
	8	Choi, et al., "Inhibition of Neointimal Hyperplasia by Blocking $\alpha\beta$ , Integrin with a Small Peptide Antagonist OpenGRGDSPCA", <u>J. of Vasc. Surg.</u> 12: 125-134 (1994)
	9	Nicosia, et al., "Inhibition of Angiogenesis in vitro by Arg-Gly-Asp-Containing Synthetic Peptide", <u>Amer. Jour. of Pathol.</u> 138 (4): 829-833 (1991)
	10	Cheresh, et al., "Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor", <u>J. of Bio. Chem.</u> 262 (36): 17703-17711 (1987)
<i>W</i>	11	Leavesley, et al., "Integrin $\beta$ 1- and $\beta$ 3-mediated Endothelial Cell Migration is Triggered through Distinct Signaling Mechanisms", <u>J. of Cell Biol.</u> 121: 163-170 (1993)
EXAMINER		
<i>Gmigel 4/9/01</i>		
DATE CONSIDERED		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>	<b>ATTY DOCKET NO.</b> TSRI 419.0 Con 1	<b>SERIAL NO.</b> 09/081,522
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		
<b>APPLICANT</b> Brooks, et al.		
<b>FILING DATE</b> 5/19/98		<b>GROUP</b> 1648 <i>1644</i>

## U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE



## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

<i>Mc</i>	12	Swerlick, et al., "Expression and Modulation of the Vitronectin Receptor on Human Dermal Microvascular Endothelial Cells", <u>J. of Inves. Derm.</u> 99 (6): 715-722 (1992)
	13	Brooks, et al., "Subtractive Immunization Yields Monoclonal Antibodies that Specifically Inhibit Metastasis", <u>J. of Cell Biol.</u> 122 (6): 1351-1359 (1993)
	14	Nip, et al., "Human Melanoma Cells Derived from Lymphatic Metastases Use Integrin $\alpha_5\beta_1$ to Adhere to Lymph Node Vitronectin", <u>J. Clin. Invest.</u> 90: 1406-1413 (1992)
	15	Jackson, et al., "Isolation and Propagation of Endothelial Cells Derived from Rheumatoid Synovial Microvasculature", <u>Ann. of the Rheu. Dis.</u> 48: 733-736 (1989)
	16	Waldman, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy", <u>Science</u> 252: 1657-1662 (1991)
	17	Brooks, et al., "Requirement of Vascular Integrin $\alpha_5\beta_1$ for Angiogenesis", <u>Science</u> 264: 569-570 (1994)
	18	Chuntharapai, et al., "Blocking Monoclonal Antibodies to $\alpha V\beta 3$ Integrin: A Unique Epitope of $\alpha V\beta 3$ Integrin is Present on Human Osteoclasts", <u>Exper. Cell Res.</u> 205: 345-352 (1993)
	19	Osband, et al., "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy", <u>Imm. Today</u> 11 (6): 193-195 (1990)
<i>Mc</i>	20	Ausprunk, et al., "Vascularization of Normal and Neoplastic Tissues Grafted to the Chick Chorioallantois", <u>Amer. J. of Path.</u> 79 (3): 597-610 (1975)
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <b>EXAMINER</b>  <i>GMADEL 4/9/01</i> </div> <div style="width: 45%;"> <b>DATE CONSIDERED</b>  </div> </div>		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>				<b>ATTY DOCKET NO.</b> TSRI 419.0 Con 1		<b>SERIAL NO.</b> 09/081,522	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>APPLICANT</b> Brooks, et al.			
				<b>FILING DATE</b> 5/19/98		<b>GROUP</b> 1648 1644	
<b>U.S. PATENT DOCUMENTS</b>							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE



<b>FOREIGN PATENT DOCUMENTS</b>							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

<div style="text-align: center;">M</div>	21	Cheresh, et al., "Recognition of Distinct Adhesive Sites on Fibrinogen by Related Integrins on Platelets and Endothelial Cells", <u>Cell</u> 58: 945-953 (1989)		
	22	D'Amato, et al., "Thalidomide is an Inhibitor of Angiogenesis", <u>Proc. Natl. Acad. Sci. USA</u> 91: 4082-4085 (1994)		
	23	Leibovich, et al., "Macrophage-induced Angiogenesis is Mediated by Tumour Necrosis Factor- $\alpha$ ", <u>Nature</u> 329: 630-632 (1987)		
	24	Pfaff, et al., "Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by $\alpha$ lib $\beta$ 3, and $\alpha$ 5 $\beta$ 1 Integrins", <u>J. of Biol. Chem.</u> 269 (32): 20233-20238 (1994)		
	25	Yan, et al., "Human/Severe Combined Immunodeficient Mouse Chimeras: An Experimental in Vivo Model System to Study the Regulation of Human Endothelial Cell-Leukocyte Adhesion Molecules", <u>J. Clin. Invest.</u> 91: 986-996 (1993)		
	26	Gurrath, et al., "Conformation/Activity Studies of Rationally Designed Potent Anti-Adhesive RGD Peptides", <u>Eur. J. Biochem</u> 210: 911-921 (1992)		
	27	Leven, et al., "Extracellular Matrix Stimulation of Guinea Pig Megakaryocyte Proplatelet Formation in vitro Is Mediated Through the Vitronectin Receptor", <u>Exp. Hematol.</u> 20: 1316-1322 (1992)		
	28	Laffrenie, et al., "Up-regulated Biosynthesis and Expression of Endothelial Cell Vitronectin Receptor Enhances Cancer Cell Adhesion", <u>Canc. Res.</u> 52: 2202-2208 (1992)		
<div style="text-align: center;">M</div>	29	Klein, et al., "Basic Fibroblast Growth Factor Modulates Integrin Expression in Microvascular Endothelial Cells", <u>Mol. Bio. of the Cell</u> 4: 973-982 (1993)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; padding: 5px;"> <b>EXAMINER</b>  <div style="text-align: center;">GAMGEL 4/9/01</div> </td> <td style="width: 50%; border: none; padding: 5px;"> <b>DATE CONSIDERED</b> </td> </tr> </table>			<b>EXAMINER</b> <div style="text-align: center;">GAMGEL 4/9/01</div>	<b>DATE CONSIDERED</b>
<b>EXAMINER</b> <div style="text-align: center;">GAMGEL 4/9/01</div>	<b>DATE CONSIDERED</b>			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.  
MC/C/WP/IDS/MER0046P.449